Genmab Merus acquisition for $8 billion enhances its oncology portfolio with innovative therapies like Petosemtamab.
• Genmab acquires Merus for $8 billion.
• Acquisition includes Petosemtamab, a late-stage asset.
• Enhances Genmab’s oncology portfolio and growth potential.
Genmab has announced the acquisition of Merus in a transaction valued at $8 billion, significantly enhancing its oncology portfolio. This strategic move includes the addition of Petosemtamab, a late-stage breakthrough therapy asset, which is expected to bolster Genmab’s position in the cancer treatment market. The acquisition aligns with Genmab’s strategy to expand its pipeline with innovative therapies that address unmet medical needs in oncology.
The deal, which was finalized on 10 September 2025, marks a substantial investment by Genmab in its future growth prospects. Petosemtamab, a promising candidate in late-stage development, is anticipated to play a crucial role in Genmab’s efforts to deliver cutting-edge cancer treatments. The acquisition not only strengthens Genmab’s existing portfolio but also provides access to Merus’s proprietary technology platforms and expertise in bispecific antibody development.
According to the terms of the agreement, Genmab will gain full rights to Merus’s assets, including Petosemtamab, which has shown encouraging results in clinical trials. The therapy has demonstrated significant efficacy in treating certain types of cancer, with response rates exceeding expectations. This acquisition positions Genmab to compete more effectively in the oncology space, where demand for innovative treatments continues to grow.
The global oncology market is projected to reach $250 billion by 2030, driven by advancements in personalized medicine and targeted therapies. Genmab’s acquisition of Merus is a strategic response to this trend, enabling the company to leverage its expanded portfolio to capture a larger share of the market. Moreover, the addition of Petosemtamab is expected to enhance Genmab’s competitive edge against other major players in the industry.
As a result of this acquisition, Genmab anticipates an increase in its research and development capabilities, allowing for accelerated progress in its clinical programs. The company plans to integrate Merus’s operations seamlessly, ensuring continuity in ongoing projects and maximizing the potential of its newly acquired assets.
For more insights on M&A and Licensing, visit our M&A and Licensing section.